Enhancing immunotherapy effectiveness for triple negative breast cancer
Official title: Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer
Funded at Promilead, LLC · NIH-11065977 · Data updated 2026-11-12
This study is looking at how a special protein called TFEB can help make immunotherapy work better for people with triple negative breast cancer, which is a tough type of cancer that doesn't always respond well to current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Promilead, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $400,000 |
| NIH project number | 1R41CA298141-01 |
| Project ID | NIH-11065977 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are seeking new treatment options.
✕Less likely to help
Patients with other subtypes of breast cancer or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates how activating a specific protein, TFEB, can improve the effectiveness of immunotherapy treatments for patients with triple negative breast cancer (TNBC). TNBC is known for being particularly aggressive and often does not respond well to existing immunotherapy options. The researchers aim to combine chemotherapy with immunotherapy to enhance the immune response against the cancer. By understanding how TFEB can modify the tumor environment and immune cell behavior, the goal is to develop a more effective treatment strategy for TNBC patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with triple negative breast cancer by making immunotherapy more effective.
How similar studies have gone: Previous research has shown promising results in enhancing immunotherapy responses through similar approaches, indicating potential for success in this area.
Where this research is happening
-
Promilead, LLC
Columbia, United States Active
Researchers
- Principal investigator: Fan, Daping — Promilead, LLC
- Study coordinator: Fan, Daping
Related research
Other NIH-funded projects on the same topics.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
Determinants of Response to DNA-Damaging Radiation and Immunotherapy in Triple-Negative Breast Cancer
This grant explores why some people with triple-negative breast cancer respond to a combo of radiation, chemotherapy, and immunotherapy and why others don’t, to guide more personalized treatment.
-
New immunotherapy combo for hard-to-treat triple-negative breast cancer
Aims to test a combination immunotherapy with JNK inhibitors to improve treatment for people with triple-negative breast cancer.
-
Reprogrammed exosome immunotherapy for triple-negative breast cancer
A new treatment approach uses engineered exosomes to stimulate the immune system to fight triple-negative breast cancer in patients.
-
Engineered CD4+ T cells targeting KK‑LC‑1 for triple‑negative breast cancer
This project creates engineered CD4+ T cells that recognize the KK‑LC‑1 tumor antigen to help people with HLA‑DR13-positive triple‑negative breast cancer.
-
Why some triple-negative breast cancers respond to radiation plus immunotherapy and others resist
This project looks at whether patterns of tumor cell death and immune signals can predict and improve responses to radiation combined with anti-PD1 immunotherapy for people with early-stage triple-negative breast cancer that has spread to lymph nodes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.